Gliclazide (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gliclazide" in Italian language version.

refsWebsite

Global rank Italian rank

23nih.gov

4^th place

9^th place

9doi.org

2^nd place

7^th place

7oadoi.org

799^th place

22^nd place

6archive.org

6^th place

8^th place

1web.archive.org

1^st place

archive.org

BL. Wajchenberg, M. Nery; CE. Leme; AA. Silveira; P. Fioratti; OA. Germek, Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes., in Clin Pharmacol Ther, vol. 27, n. 3, marzo 1980, pp. 375-8, PMID 6987025.
TG. Skillman, JM. Feldman, The pharmacology of sulfonylureas., in Am J Med, vol. 70, n. 2, febbraio 1981, pp. 361-72, PMID 6781341.
CL. Lawrence, P. Proks; GC. Rodrigo; P. Jones; Y. Hayabuchi; NB. Standen; FM. Ashcroft, Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells., in Diabetologia, vol. 44, n. 8, Ago 2001, pp. 1019-25, DOI:10.1007/s001250100595, PMID 11484080.
F. Violi, GC. De Mattia; C. Alessandri; A. Perrone; E. Vezza, The effects of gliclazide on platelet function in patients with diabetes mellitus., in Curr Med Res Opin, vol. 8, n. 3, 1982, pp. 200-3, DOI:10.1185/03007998209112384, PMID 7128193.
K. Kobayashi, M. Kimura; T. Sakoguchi; A. Hase; A. Matsuoka; S. Kaneko, Pharmacokinetics of gliclazide in healthy and diabetic subjects., in J Pharm Sci, vol. 73, n. 12, Dic 1984, pp. 1684-7, PMID 6396398.
S. Chitturi, V. Le; J. Kench; C. Loh; J. George, Gliclazide-induced acute hepatitis with hypersensitivity features., in Dig Dis Sci, vol. 47, n. 5, Mag 2002, pp. 1107-10, PMID 12018908.

doi.org

dx.doi.org

T. Shimoyama, S. Yamaguchi; K. Takahashi; H. Katsuta; E. Ito; H. Seki; K. Ushikawa; H. Katahira; K. Yoshimoto; H. Ohno; S. Nagamatsu, Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation., in Metabolism, vol. 55, n. 6, Giu 2006, pp. 722-30, DOI:10.1016/j.metabol.2006.01.019, PMID 16713429.
S. Del Guerra, M. Grupillo; M. Masini; R. Lupi; M. Bugliani; S. Torri; U. Boggi; M. Del Chiaro; F. Vistoli; F. Mosca; S. Del Prato, Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose., in Diabetes Metab Res Rev, vol. 23, n. 3, marzo 2007, pp. 234-8, DOI:10.1002/dmrr.680, PMID 16952202.
N. Katakami, Y. Yamasaki; R. Hayaishi-Okano; K. Ohtoshi; H. Kaneto; M. Matsuhisa; K. Kosugi; M. Hori, Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes., in Diabetologia, vol. 47, n. 11, novembre 2004, pp. 1906-13, DOI:10.1007/s00125-004-1547-8, PMID 15565373.
CL. Lawrence, P. Proks; GC. Rodrigo; P. Jones; Y. Hayabuchi; NB. Standen; FM. Ashcroft, Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells., in Diabetologia, vol. 44, n. 8, Ago 2001, pp. 1019-25, DOI:10.1007/s001250100595, PMID 11484080.
F. Violi, GC. De Mattia; C. Alessandri; A. Perrone; E. Vezza, The effects of gliclazide on platelet function in patients with diabetes mellitus., in Curr Med Res Opin, vol. 8, n. 3, 1982, pp. 200-3, DOI:10.1185/03007998209112384, PMID 7128193.
DJ. Elliot, BC. Suharjono; EM. Lewis; DJ. Gillam; AS. Birkett; JO. Gross; . Miners, Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination., in Br J Clin Pharmacol, vol. 64, n. 4, Ott 2007, pp. 450-7, DOI:10.1111/j.1365-2125.2007.02943.x, PMID 17517049.
H. Xu, KM. Williams; WS. Liauw; M. Murray; RO. Day; AJ. McLachlan, Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide., in Br J Pharmacol, vol. 153, n. 7, aprile 2008, pp. 1579-86, DOI:10.1038/sj.bjp.0707685, PMID 18204476.
Y. Zhang, D. Si; X. Chen; N. Lin; Y. Guo; H. Zhou; D. Zhong, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects., in Br J Clin Pharmacol, vol. 64, n. 1, Lug 2007, pp. 67-74, DOI:10.1111/j.1365-2125.2007.02846.x, PMID 17298483.
G. Schernthaner, A. Grimaldi; U. Di Mario; J. Drzewoski; P. Kempler; M. Kvapil; A. Novials; R. Rottiers; GE. Rutten; KM. Shaw, GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients., in Eur J Clin Invest, vol. 34, n. 8, Ago 2004, pp. 535-42, DOI:10.1111/j.1365-2362.2004.01381.x, PMID 15305887.

nih.gov

ncbi.nlm.nih.gov

T. Shimoyama, S. Yamaguchi; K. Takahashi; H. Katsuta; E. Ito; H. Seki; K. Ushikawa; H. Katahira; K. Yoshimoto; H. Ohno; S. Nagamatsu, Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation., in Metabolism, vol. 55, n. 6, Giu 2006, pp. 722-30, DOI:10.1016/j.metabol.2006.01.019, PMID 16713429.
G. Ballagi-Pordány, A. Köszeghy; MZ. Koltai; Z. Aranyi; G. Pogátsa, Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds., in Diabetes Res Clin Pract, vol. 8, n. 2, gennaio 1990, pp. 109-14, PMID 2106423.
S. Del Guerra, M. Grupillo; M. Masini; R. Lupi; M. Bugliani; S. Torri; U. Boggi; M. Del Chiaro; F. Vistoli; F. Mosca; S. Del Prato, Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose., in Diabetes Metab Res Rev, vol. 23, n. 3, marzo 2007, pp. 234-8, DOI:10.1002/dmrr.680, PMID 16952202.
N. Katakami, Y. Yamasaki; R. Hayaishi-Okano; K. Ohtoshi; H. Kaneto; M. Matsuhisa; K. Kosugi; M. Hori, Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes., in Diabetologia, vol. 47, n. 11, novembre 2004, pp. 1906-13, DOI:10.1007/s00125-004-1547-8, PMID 15565373.
G. Schernthaner, Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects., in Metabolism, vol. 52, 8 Suppl 1, Ago 2003, pp. 29-34, PMID 12939737.
DB. Campbell, R. Lavielle; C. Nathan, The mode of action and clinical pharmacology of gliclazide: a review., in Diabetes Res Clin Pract, 14 Suppl 2, 1991, pp. S21-36, PMID 1794262.
BL. Wajchenberg, M. Nery; CE. Leme; AA. Silveira; P. Fioratti; OA. Germek, Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes., in Clin Pharmacol Ther, vol. 27, n. 3, marzo 1980, pp. 375-8, PMID 6987025.
B. Holmes, RC. Heel; RN. Brogden; TM. Speight; GS. Avery, Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus., in Drugs, vol. 27, n. 4, aprile 1984, pp. 301-27, PMID 6373223.
JE. Jackson, R. Bressler, Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1., in Drugs, vol. 22, n. 3, Set 1981, pp. 211-45, PMID 7021124.
TG. Skillman, JM. Feldman, The pharmacology of sulfonylureas., in Am J Med, vol. 70, n. 2, febbraio 1981, pp. 361-72, PMID 6781341.
MS. Greenfield, L. Doberne; M. Rosenthal; B. Schulz; A. Widstrom; GM. Reaven, Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus., in Diabetes, vol. 31, 4 Pt 1, aprile 1982, pp. 307-12, PMID 6759246.
CL. Lawrence, P. Proks; GC. Rodrigo; P. Jones; Y. Hayabuchi; NB. Standen; FM. Ashcroft, Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells., in Diabetologia, vol. 44, n. 8, Ago 2001, pp. 1019-25, DOI:10.1007/s001250100595, PMID 11484080.
RC. Paton, PB. Kernoff; JK. Wales; GP. McNicol, Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics., in Br Med J (Clin Res Ed), vol. 283, n. 6298, Ott 1981, pp. 1018-20, PMID 6794745.
F. Violi, GC. De Mattia; C. Alessandri; A. Perrone; E. Vezza, The effects of gliclazide on platelet function in patients with diabetes mellitus., in Curr Med Res Opin, vol. 8, n. 3, 1982, pp. 200-3, DOI:10.1185/03007998209112384, PMID 7128193.
A. Rieutord, I. Stupans; GM. Shenfield; AS. Gross, Gliclazide hydroxylation by rat liver microsomes., in Xenobiotica, vol. 25, n. 12, Dic 1995, pp. 1345-54, PMID 8719909.
DJ. Elliot, BC. Suharjono; EM. Lewis; DJ. Gillam; AS. Birkett; JO. Gross; . Miners, Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination., in Br J Clin Pharmacol, vol. 64, n. 4, Ott 2007, pp. 450-7, DOI:10.1111/j.1365-2125.2007.02943.x, PMID 17517049.
H. Xu, KM. Williams; WS. Liauw; M. Murray; RO. Day; AJ. McLachlan, Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide., in Br J Pharmacol, vol. 153, n. 7, aprile 2008, pp. 1579-86, DOI:10.1038/sj.bjp.0707685, PMID 18204476.
Y. Zhang, D. Si; X. Chen; N. Lin; Y. Guo; H. Zhou; D. Zhong, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects., in Br J Clin Pharmacol, vol. 64, n. 1, Lug 2007, pp. 67-74, DOI:10.1111/j.1365-2125.2007.02846.x, PMID 17298483.
K. Kobayashi, M. Kimura; T. Sakoguchi; A. Hase; A. Matsuoka; S. Kaneko, Pharmacokinetics of gliclazide in healthy and diabetic subjects., in J Pharm Sci, vol. 73, n. 12, Dic 1984, pp. 1684-7, PMID 6396398.
G. Schernthaner, A. Grimaldi; U. Di Mario; J. Drzewoski; P. Kempler; M. Kvapil; A. Novials; R. Rottiers; GE. Rutten; KM. Shaw, GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients., in Eur J Clin Invest, vol. 34, n. 8, Ago 2004, pp. 535-42, DOI:10.1111/j.1365-2362.2004.01381.x, PMID 15305887.
SP. Dourakis, E. Tzemanakis; C. Sinani; G. Kafiri; SJ. Hadziyannis, Gliclazide-induced acute hepatitis., in Eur J Gastroenterol Hepatol, vol. 12, n. 1, gennaio 2000, pp. 119-21, PMID 10656221.
H. Caksen, M. Kendirci; A. Tutuş; K. Uzüm; S. Kurtoğlu, Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt., in J Pediatr Endocrinol Metab, vol. 14, n. 8, pp. 1157-9, PMID 11592575.
S. Chitturi, V. Le; J. Kench; C. Loh; J. George, Gliclazide-induced acute hepatitis with hypersensitivity features., in Dig Dis Sci, vol. 47, n. 5, Mag 2002, pp. 1107-10, PMID 12018908.

oadoi.org

T. Shimoyama, S. Yamaguchi; K. Takahashi; H. Katsuta; E. Ito; H. Seki; K. Ushikawa; H. Katahira; K. Yoshimoto; H. Ohno; S. Nagamatsu, Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation., in Metabolism, vol. 55, n. 6, Giu 2006, pp. 722-30, DOI:10.1016/j.metabol.2006.01.019, PMID 16713429.
S. Del Guerra, M. Grupillo; M. Masini; R. Lupi; M. Bugliani; S. Torri; U. Boggi; M. Del Chiaro; F. Vistoli; F. Mosca; S. Del Prato, Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose., in Diabetes Metab Res Rev, vol. 23, n. 3, marzo 2007, pp. 234-8, DOI:10.1002/dmrr.680, PMID 16952202.
N. Katakami, Y. Yamasaki; R. Hayaishi-Okano; K. Ohtoshi; H. Kaneto; M. Matsuhisa; K. Kosugi; M. Hori, Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes., in Diabetologia, vol. 47, n. 11, novembre 2004, pp. 1906-13, DOI:10.1007/s00125-004-1547-8, PMID 15565373.
DJ. Elliot, BC. Suharjono; EM. Lewis; DJ. Gillam; AS. Birkett; JO. Gross; . Miners, Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination., in Br J Clin Pharmacol, vol. 64, n. 4, Ott 2007, pp. 450-7, DOI:10.1111/j.1365-2125.2007.02943.x, PMID 17517049.
H. Xu, KM. Williams; WS. Liauw; M. Murray; RO. Day; AJ. McLachlan, Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide., in Br J Pharmacol, vol. 153, n. 7, aprile 2008, pp. 1579-86, DOI:10.1038/sj.bjp.0707685, PMID 18204476.
Y. Zhang, D. Si; X. Chen; N. Lin; Y. Guo; H. Zhou; D. Zhong, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects., in Br J Clin Pharmacol, vol. 64, n. 1, Lug 2007, pp. 67-74, DOI:10.1111/j.1365-2125.2007.02846.x, PMID 17298483.
G. Schernthaner, A. Grimaldi; U. Di Mario; J. Drzewoski; P. Kempler; M. Kvapil; A. Novials; R. Rottiers; GE. Rutten; KM. Shaw, GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients., in Eur J Clin Invest, vol. 34, n. 8, Ago 2004, pp. 535-42, DOI:10.1111/j.1365-2362.2004.01381.x, PMID 15305887.

web.archive.org

J.R. Karmoker, R.J. Priya, S. Sarkar e S. Islam, Comparative in vitro equivalence evaluation of some local Gliclazide brands of Bangladesh (PDF), in The Pharma Innovation Journal, vol. 6, 2017, pp. 152-157. URL consultato il 15 agosto 2017 (archiviato dall'url originale il 17 marzo 2017).